Population-standardized genetic risk score: the SNP-based method of choice for inherited risk assessment of prostate cancer
- PMID: 27080480
- PMCID: PMC4955173
- DOI: 10.4103/1008-682X.179527
Population-standardized genetic risk score: the SNP-based method of choice for inherited risk assessment of prostate cancer
Abstract
Several different approaches are available to clinicians for determining prostate cancer (PCa) risk. The clinical validity of various PCa risk assessment methods utilizing single nucleotide polymorphisms (SNPs) has been established; however, these SNP-based methods have not been compared. The objective of this study was to compare the three most commonly used SNP-based methods for PCa risk assessment. Participants were men (n = 1654) enrolled in a prospective study of PCa development. Genotypes of 59 PCa risk-associated SNPs were available in this cohort. Three methods of calculating SNP-based genetic risk scores (GRSs) were used for the evaluation of individual disease risk such as risk allele count (GRS-RAC), weighted risk allele count (GRS-wRAC), and population-standardized genetic risk score (GRS-PS). Mean GRSs were calculated, and performances were compared using area under the receiver operating characteristic curve (AUC) and positive predictive value (PPV). All SNP-based methods were found to be independently associated with PCa (all P < 0.05; hence their clinical validity). The mean GRSs in men with or without PCa using GRS-RAC were 55.15 and 53.46, respectively, using GRS-wRAC were 7.42 and 6.97, respectively, and using GRS-PS were 1.12 and 0.84, respectively (all P < 0.05 for differences between patients with or without PCa). All three SNP-based methods performed similarly in discriminating PCa from non-PCa based on AUC and in predicting PCa risk based on PPV (all P > 0.05 for comparisons between the three methods), and all three SNP-based methods had a significantly higher AUC than family history (all P < 0.05). Results from this study suggest that while the three most commonly used SNP-based methods performed similarly in discriminating PCa from non-PCa at the population level, GRS-PS is the method of choice for risk assessment at the individual level because its value (where 1.0 represents average population risk) can be easily interpreted regardless of the number of risk-associated SNPs used in the calculation.
Similar articles
-
Reclassification of prostate cancer risk using sequentially identified SNPs: Results from the REDUCE trial.Prostate. 2017 Aug;77(11):1179-1186. doi: 10.1002/pros.23369. Epub 2017 Jul 2. Prostate. 2017. PMID: 28670847 Free PMC article. Clinical Trial.
-
Single-Nucleotide Polymorphism-Based Genetic Risk Score and Patient Age at Prostate Cancer Diagnosis.JAMA Netw Open. 2019 Dec 2;2(12):e1918145. doi: 10.1001/jamanetworkopen.2019.18145. JAMA Netw Open. 2019. PMID: 31880795 Free PMC article.
-
Race-specific genetic risk score is more accurate than nonrace-specific genetic risk score for predicting prostate cancer and high-grade diseases.Asian J Androl. 2016 Jul-Aug;18(4):525-9. doi: 10.4103/1008-682X.179857. Asian J Androl. 2016. PMID: 27140652 Free PMC article.
-
Clinical validity and utility of genetic risk scores in prostate cancer.Asian J Androl. 2016 Jul-Aug;18(4):509-14. doi: 10.4103/1008-682X.182981. Asian J Androl. 2016. PMID: 27297129 Free PMC article. Review.
-
A comparison of genetic risk score with family history for estimating prostate cancer risk.Asian J Androl. 2016 Jul-Aug;18(4):515-9. doi: 10.4103/1008-682X.177122. Asian J Androl. 2016. PMID: 27004541 Free PMC article. Review.
Cited by
-
Systematic evaluation of cancer-specific genetic risk score for 11 types of cancer in The Cancer Genome Atlas and Electronic Medical Records and Genomics cohorts.Cancer Med. 2019 Jun;8(6):3196-3205. doi: 10.1002/cam4.2143. Epub 2019 Apr 9. Cancer Med. 2019. PMID: 30968590 Free PMC article.
-
Selecting variants of unknown significance through network-based gene-association significantly improves risk prediction for disease-control cohorts.Sci Rep. 2019 Mar 1;9(1):3266. doi: 10.1038/s41598-019-39796-w. Sci Rep. 2019. PMID: 30824863 Free PMC article.
-
Reclassification of prostate cancer risk using sequentially identified SNPs: Results from the REDUCE trial.Prostate. 2017 Aug;77(11):1179-1186. doi: 10.1002/pros.23369. Epub 2017 Jul 2. Prostate. 2017. PMID: 28670847 Free PMC article. Clinical Trial.
-
Translation of genomics and epigenomics in prostate cancer: progress and promising directions.Asian J Androl. 2016 Jul-Aug;18(4):503-4. doi: 10.4103/1008-682X.182820. Asian J Androl. 2016. PMID: 27270344 Free PMC article.
-
Prioritization of Variants for Investigation of Genotype-Directed Nutrition in Human Superpopulations.Int J Mol Sci. 2019 Jul 18;20(14):3516. doi: 10.3390/ijms20143516. Int J Mol Sci. 2019. PMID: 31323740 Free PMC article.
References
-
- Moyer VA. U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157:120–34. - PubMed
-
- Hayes JH, Barry MJ. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. JAMA. 2014;311:1143–9. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous